These results are consistent with previous findings that EGFR downregulation after treatment with cetuximab or panitumumab predicts the antitumor effect in CRC [42] and that HER2 amplification confers resistance to anti-EGFR therapy in CRC [8]. Here, ERBB2 is linked to colorectal carcinoma.